Trial Drug Shows Promise in Treating Cognitive Impairment Associated with Schizophrenia

Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a treatment for cognitive impairment associated with schizophrenia (CIAS). Study data shows that a single dose of CVN058 elicited a statistically significant improvement in mismatch negativity (MMN), an auditory evoked potential generated in the cerebral cortex that is typically impaired in schizophrenics, David H. Margolin, senior vice president of clinical and translational medicine at Cerevance, told BioSpace in an interview.